Form SC 13G XENOPORT INC Filed by: QVT Financial LP Nov 18, 2009 09:58AM

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6612969


Form 13F-HR QVT Financial LP For: Sep 30 Nov 16, 2009 09:19AM

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6605768


Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer Nov 4, 2009 08:15AM

Company advances 3rd internally discovered program into clinical studies CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-b superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor. The Phase 1 trial is a multiple-dose, dose-escalating study designed to assess the ...


Form SC 13G INHIBITEX, INC. Filed by: QVT Financial LP Oct 30, 2009 11:03AM

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6574596


QVT Financial Boosts Stake in Cytokinetics (CYTK) to 8.44%, Profits From Yesterday's Big Surge May 27, 2009 09:45AM

In a 13G filing on Cytokinetics Inc. (Nasdaq: CYTK), QVT Financial LP dislosed an 8.44% stake, 5,126,627 shares, in the company ...




Mar 3, 2008 02:17PM Genesco's (GCO) Largest Shareholder, QVT, Opposes Settlement